Key Takeaways
Jaguar Health, Inc. (NASDAQ:JAGX) reported a first-quarter revenue increase of 816 percent year-over-year, fueled by a licensing agreement that shifts its focus to rare-disease drug development.
"The key event was the closing of a U.S. out-license agreement with Future Pak for Mytesi...fully aligned with our strategy to sharply focus our crofelemer development efforts on rare-disease intestinal failure indications," CEO Lisa Conte said on the company's fourth-quarter 2025 earnings call.
The dramatic revenue growth was primarily driven by the recognition of a significant portion of an $18 million upfront payment from the Future Pak deal, of which Jaguar received $16 million in cash in January 2026. The agreement licenses U.S. commercial rights for Mytesi and Canalevia-CA1, with Jaguar retaining manufacturing rights at a premium price. The company did not disclose earnings per share in its initial announcement.
This deal provides Jaguar with non-dilutive funding to advance its pipeline for rare gastrointestinal conditions, including microvillus inclusion disease and short bowel syndrome. The strategic shift allows the company to offload commercial responsibilities for its Mytesi product, where prescription volumes had declined 12.2 percent year-over-year in the fourth quarter of 2025, and focus resources on its higher-potential clinical programs.
The company will hold an investor webcast on May 26 at 8:30 a.m. Eastern to review the first-quarter financials. CEO Lisa Conte is also scheduled to present at the Lytham Partners Spring 2026 Investor Conference on May 28.
This article is for informational purposes only and does not constitute investment advice.
